GlobeNewswire

PCI Biotech: Publication of case report series from the Phase I study in bile duct cancer

Share

Oslo (Norway), 19 August 2020 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announced that a case report series from the Phase I study with PCI Biotech's proprietary drug fimaporfin (AmphinexTM), for the treatment of inoperable extrahepatic bile duct cancer (eCCA), is accepted for publishing in Endoscopy International Open. The article has the title "Photochemical Internalisation and gemcitabine combined with first-line chemotherapy in perihilar cholangiocarcinoma – observations in three patients" and will soon be available online.

Professor Jörg Trojan, one of the key investigators in the Phase I trial and global coordinating investigator for the pivotal RELEASE study, said: “These selected cases from the Phase I study are really encouraging and nicely demonstrates the apparent positive treatment potential of the fimaChem technology in patients with inoperable bile duct cancer. I look forward to work together with my colleagues in the RELEASE study to see whether these effects can be translated to an efficacious treatment across a larger patient population.”

Endoscopy International Open (EIO) is an open access journal in the field of gastrointestinal endoscopy. It covers all aspects of endoscopic diagnosis, therapeutic procedures and technical developments. EIO offers a fast and independent quality process with free, broad and easy access for everybody, and all articles submitted to EIO undergo rigorous blind scientific peer review. 

Contact information:                  
Per Walday, CEO
pw@pcibiotech.no
Mobile: +47 917 93 429

About PCI Biotech
PCI Biotech is a biopharmaceutical late stage clinical development company focusing on development and commercialisation of novel therapies for the treatment of cancer through its innovative photochemical internalisation (PCI) technology platform.  PCI is applied to three distinct anticancer paradigms: fimaChem (enhancement of chemotherapeutics for localised treatment of cancer), fimaVacc (T-cell induction technology for therapeutic vaccination), and fimaNAc (nucleic acid therapeutics delivery).

Photochemical internalisation induces triggered endosomal release that is used to unlock the true potential of a wide array of therapeutic modalities. The company’s lead programme fimaChem consists of a pivotal study in bile duct cancer, an orphan indication with a high unmet need and without approved products. fimaVacc applies a unique mode of action to enhance the essential cytotoxic effect of therapeutic cancer vaccines, which works in synergy with several other state-of-the-art vaccination technologies. fimaNAc utilises the endosomal release to provide intracellular delivery of nucleic acids, such as mRNA and RNAi therapeutics, thereby addressing one of the major bottlenecks facing this emerging and promising field.

For further information, please visit: www.pcibiotech.com

Forward-looking statements  
This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements. PCI Biotech disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

HALF-YEAR RESULTS 2020: UNIBAIL-RODAMCO-WESTFIELD N.V.25.9.2020 20:00:00 CESTPress release

Amsterdam, September 25, 2020 Press Release HALF-YEAR RESULTS 2020: UNIBAIL-RODAMCO-WESTFIELD N.V. On September 25, 2020, Unibail-Rodamco-Westfield N.V. (“URW NV”) announced its 2020 half-year results and released its consolidated interim financial statements for the period ending June 30, 2020, which can be found on: https://www.urw-nv.com/en/investors/press-releases https://www.urw-nv.com/en/investors/press-releases and as an attachment to this press release. URW NV and its consolidated entities, together with Unibail-Rodamco-Westfield SE (“URW SE”) and its consolidated entities, form Unibail-Rodamco-Westfield (“URW”). URW SE consolidates URW NV and its controlled undertakings, and its 2020 half-year results represent a comprehensive overview of URW, and is available on: https://www.urw.com/en/investors/financial-information/financial-results https://www.urw.com/en/investors/financial-information/financial-results For further information, please contact: Investor Relations Media Rela

EUROPEAN  COMMISSION  GRANTS  MARKETING  AUTHORIZATION FOR JYSELECA® (FILGOTINIB)  FOR  THE  TREATMENT  OF  ADULTS  WITH  MODERATE  TO  SEVERE ACTIVE  RHEUMATHOID  ARTHRITIS25.9.2020 19:00:00 CESTPress release

-- Jyseleca® Demonstrated Durable Efficacy Combined with a Consistent Safety Profile in Rheumatoid Arthritis Through 52 Weeks in Phase 3 Clinical Development Program -- Foster City, Calif., & Mechelen, Belgium, September 25, 2020, 19.00 CET – Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & Nasdaq: GLPG) today announced that the European Commission (EC) has granted marketing authorization for Jyseleca® (filgotinib 200 mg and 100 mg tablets), a once-daily, oral, JAK1 inhibitor for the treatment of adults with moderate to severe active rheumatoid arthritis (RA) who have responded inadequately to, or are intolerant to, one or more disease modifying anti-rheumatic drugs (DMARDs). Jyseleca may be used as monotherapy or in combination with methotrexate (MTX).1 RA is a chronic, progressive, systemic, inflammatory disease that can lead to significant and irreversible joint destruction, pain and functional impairment.2 Almost 3 million people in Europe are living with RA,3 many

Correction: CONDITIONS FOR RIKSBANK REVERSED AUCTIONS SEK COVERED BONDS25.9.2020 17:10:39 CESTPress release

Sveriges Riksbank Bid procedure details Covered Bonds, 2020-10-01 Maturity dateLoanISIN codeCouponVolume, SEK million2023-09-20 5533 SE00104427311.25 %1,000 +/- 5002023-12-01 576 SE00100498411.00 %1,000 +/- 500 2023-06-011587SE00104413031.50 %1,000 +/- 5002023-12-20193SE00110896221.00 %1,000 +/- 5002023-12-202312SE00111164741.00 %300 +/- 1502023-09-20516SE00091903901.25 %600 +/- 2502023-06-21144SE00111674281.00 %600 +/- 250 Settlement date 2020-10-05 Bids have to be entered by 10.00 on OCT 1, 2020 Highest permitted bid volume: 1,000 SEK million in issue 5533 1,000 SEK million in issue 576 1,000 SEK million in issue 1587 1,000 SEK million in issue 193 300 SEK million in issue 2312 600 SEK million in issue 516 600 SEK million in issue 144 Maximum volume 5.5 billion SEK in total Lowest permitted bid volume: 50 SEK million Bids only through counterparties approved by the Riksbank RESULT OF AUCTION WILL BE PUBLISHED NO LATER THAN 10.15 (CEST) ON OCT 1, 2020. For more information, please con

Correction: CONDITIONS FOR RIKSBANK REVERSED AUCTIONS SEK COVERED BONDS25.9.2020 17:10:00 CESTPress release

Sveriges Riksbank Bid procedure details Covered Bonds, 2020-10-01 Maturity dateLoanISIN codeCouponVolume, SEK million2023-09-20 5533 SE00104427311.25 %1,000 +/- 5002023-12-01 576 SE00100498411.00 %1,000 +/- 500 2023-06-011587SE00104413031.50 %1,000 +/- 5002023-12-20193SE00110896221.00 %1,000 +/- 5002023-12-202312SE00111164741.00 %300 +/- 1502023-09-20516SE00091903901.25 %600 +/- 2502023-06-21144SE00111674281.00 %600 +/- 250 Settlement date 2020-10-05 Bids have to be entered by 10.00 on OCT 1, 2020 Highest permitted bid volume: 1,000 SEK million in issue 5533 1,000 SEK million in issue 576 1,000 SEK million in issue 1587 1,000 SEK million in issue 193 300 SEK million in issue 2312 600 SEK million in issue 516 600 SEK million in issue 144 Maximum volume 5.5 billion SEK in total Lowest permitted bid volume: 50 SEK million Bids only through counterparties approved by the Riksbank RESULT OF AUCTION WILL BE PUBLISHED NO LATER THAN 10.15 (CEST) ON OCT 1, 2020. For more information, please con

CONDITIONS FOR RIKSBANK REVERSED AUCTIONS SEK COVERED BONDS25.9.2020 16:20:00 CESTPress release

Sveriges Riksbank Bid procedure details Covered Bonds, 2020-10-01 Maturity dateLoanISIN codeCouponVolume, SEK million2023-09-20 5533 SE00104427311.25 %1,000 +/- 5002023-12-01 578 SE00026959244.25 %1,000 +/- 500 2023-06-011587SE00104413031.50 %1,000 +/- 5002023-12-20193SE00110896221.00 %1,000 +/- 5002023-12-202312SE00111164741.00 %300 +/- 1502023-09-20516SE00091903901.25 %600 +/- 2502023-06-21144SE00111674281.00 %600 +/- 250 Settlement date 2020-10-05 Bids have to be entered by 10.00 on OCT 1, 2020 Highest permitted bid volume: 1,000 SEK million in issue 5533 1,000 SEK million in issue 578 1,000 SEK million in issue 1587 1,000 SEK million in issue 193 300 SEK million in issue 2312 600 SEK million in issue 516 600 SEK million in issue 144 Maximum volume 5.5 billion SEK in total Lowest permitted bid volume: 50 SEK million Bids only through counterparties approved by the Riksbank RESULT OF AUCTION WILL BE PUBLISHED NO LATER THAN 10.15 (CEST) ON OCT 1, 2020. For more information, please con

CONDITIONS FOR RIKSBANK BID PROCEDURE KOMMUNINVEST BONDS25.9.2020 16:20:00 CESTPress release

Sveriges Riksbank Bid procedure details Kommuninvest Bonds, 2020-09-29 Maturity dateLoanISIN codeCouponVolume, SEK million2022-06-012206SE00092694180.25 %1,100 +/- 2502023-11-132311SE00109482401.00 %1,100 +/- 2502025-05-12 2505 SE0011414010 1.00 % 1,100 +/- 250 2026-11-12 2611 SE0012569572 1.00 % 1,100 +/- 250 Maximum volume 4 310 million in total Settlement date 2020-10-01 Bids have to be entered by 11.00 on SEP 29, 2020 Highest permitted bid volume: 1 100 SEK million in issue 2206, 2311, 2505, and 2611. Lowest permitted bid volume: 50 SEK million Bids only through counterparties approved by the Riksbank RESULT OF AUCTION WILL BE PUBLISHED NO LATER THAN 11.15 (CEST) ON SEP 29, 2020 For more information, please contact: Trading desk at the Riksbank + 46 8 696 6970 General and special terms and conditions can be retrieved at http://www.riksbank.se